Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM?3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes

Brunner, Andrew M., Esteve, Jordi, Porkka, Kimmo, Knapper, Steve ORCID: https://orcid.org/0000-0002-6405-4441, Traer, Elie, Scholl, Sebastian, Garcia-Manero, Guillermo, Vey, Norbert, Wermke, Martin, Janssen, Jeroen J. W. M., Narayan, Rupa, Fleming, Shaun, Loo, Sun, Tovar, Natalia, Kontro, Mika, Ottmann, Oliver G., Naidu, Purushotham, Sun, Haiying, Han, May, White, Roisin, Zhang, Na, Mohammed, Anisa, Sabatos?Peyton, Catherine A., Steensma, David P., Rinne, Mikael L., Borate, Uma M. and Wei, Andrew H. 2024. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM?3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. American Journal of Hematology 99 (2) , E32-E36. 10.1002/ajh.27161
Item availability restricted.

[thumbnail of KNAPPER, STEVE - Phase Ib study of sabatolimab (MBG453).pdf] PDF - Accepted Post-Print Version
Restricted to Repository staff only until 22 November 2024 due to copyright restrictions.

Download (320kB)

Abstract

The safety and efficacy of sabatolimab, a novel immunotherapy targeting T-cell immunoglobulin domain and mucin domain-3 (TIM-3), was assessed in combination with hypomethylating agents (HMAs) in patients with HMA-naive revised International Prognostic System Score (IPSS-R) high- or very high-risk myelodysplastic syndromes (HR/vHR-MDS) or chronic myelomonocytic leukemia (CMML). Sabatolimab + HMA had a safety profile similar to that reported for HMA alone and demonstrated durable clinical responses in patients with HR/vHR-MDS. These results support the ongoing evaluation of sabatolimab-based combination therapy in MDS, CMML, and acute myeloid leukemia.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Publisher: Wiley
ISSN: 0361-8609
Date of First Compliant Deposit: 6 February 2024
Date of Acceptance: 2 November 2023
Last Modified: 12 Feb 2024 12:27
URI: https://orca.cardiff.ac.uk/id/eprint/166141

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics